en.Wedoany.com Reported - IDEAYA Biosciences, Inc., a precision medicine oncology company in the United States, announced that the first patient has been enrolled in the dose-escalation phase of the Phase 1 clinical trial for its potential first-in-class oral small molecule drug, IDE574. This study primarily targets patients with solid tumors that have high unmet needs, such as breast, prostate, colorectal, and lung cancers, focusing on evaluating the safety, efficacy, and pharmacokinetic profile of IDE574 as a monotherapy.
IDE574 is a selective and equipotent dual inhibitor targeting lysine acetyltransferase (KAT)6 and 7 homologs. KAT6 and KAT7, as epigenetic regulators, are often dysregulated during oncogenic transformation and support cancer cell survival. Preclinical data show that IDE574 exhibits extremely high cellular potency and possesses a selectivity window of up to 350 to 2000-fold relative to KAT5 and KAT8, which are essential for maintaining normal cellular functions. This marks a significant breakthrough in reducing off-target effects and enhancing treatment precision.
In terms of clinical application, the core value of this drug lies in addressing cancer drug resistance and tumor heterogeneity. Particularly for breast cancer patients harboring estrogen receptor 1 (ESR1) mutations, which occur in 10% to 50% of cases during endocrine therapy and are a key cause of treatment failure. Yujiro S. Hata, President and CEO of IDEAYA Biosciences, stated that IDE574's unique novel chromatin remodeling mechanism provides a new monotherapy pathway for treating patients who have developed resistance to hormonal therapies.
Validated in preclinical solid tumor models, IDE574 demonstrated significantly superior anti-tumor activity compared to traditional single KAT6 inhibition strategies. Dr. Michael White, Chief Scientific Officer of IDEAYA Biosciences, pointed out that the research on this dual inhibitor aims to deliver deeper and more durable anti-tumor responses for patients than historical clinical data.
The initiation of this Phase 1 trial not only represents a significant advancement for IDEAYA Biosciences in the field of epigenetics but also provides an innovative weapon to address the complex issue of cancer drug resistance. As the research progresses, IDE574 is expected to become an important therapeutic option for various advanced solid tumors. It may also form rational combination therapy strategies with other assets in the company's pipeline, further expanding the boundaries of precision medicine.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
